nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosaprepitant—Angioedema—Methylprednisolone—psoriatic arthritis	0.00218	0.00218	CcSEcCtD
Fosaprepitant—Abdominal discomfort—Methotrexate—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Erythema—Dexamethasone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Erythema—Betamethasone—psoriatic arthritis	0.00217	0.00217	CcSEcCtD
Fosaprepitant—Malaise—Triamcinolone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Fosaprepitant—Malaise—Methylprednisolone—psoriatic arthritis	0.00215	0.00215	CcSEcCtD
Fosaprepitant—Syncope—Triamcinolone—psoriatic arthritis	0.00214	0.00214	CcSEcCtD
Fosaprepitant—Syncope—Methylprednisolone—psoriatic arthritis	0.00214	0.00214	CcSEcCtD
Fosaprepitant—Connective tissue disorder—Prednisone—psoriatic arthritis	0.00213	0.00213	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisolone—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Oedema—Prednisolone—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Dysuria—Methotrexate—psoriatic arthritis	0.00212	0.00212	CcSEcCtD
Fosaprepitant—Loss of consciousness—Triamcinolone—psoriatic arthritis	0.0021	0.0021	CcSEcCtD
Fosaprepitant—Loss of consciousness—Methylprednisolone—psoriatic arthritis	0.00209	0.00209	CcSEcCtD
Fosaprepitant—Shock—Prednisolone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Fosaprepitant—Cough—Triamcinolone—psoriatic arthritis	0.00208	0.00208	CcSEcCtD
Fosaprepitant—Photosensitivity reaction—Methotrexate—psoriatic arthritis	0.00207	0.00207	CcSEcCtD
Fosaprepitant—Hypertension—Triamcinolone—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Hypertension—Methylprednisolone—psoriatic arthritis	0.00206	0.00206	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Prednisolone—psoriatic arthritis	0.00205	0.00205	CcSEcCtD
Fosaprepitant—Eye disorder—Prednisone—psoriatic arthritis	0.00203	0.00203	CcSEcCtD
Fosaprepitant—Anxiety—Methylprednisolone—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Infestation NOS—Methotrexate—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Infestation—Methotrexate—psoriatic arthritis	0.00202	0.00202	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Flushing—Prednisone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Dexamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Betamethasone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Discomfort—Triamcinolone—psoriatic arthritis	0.00201	0.00201	CcSEcCtD
Fosaprepitant—Discomfort—Methylprednisolone—psoriatic arthritis	0.002	0.002	CcSEcCtD
Fosaprepitant—Stevens-Johnson syndrome—Methotrexate—psoriatic arthritis	0.002	0.002	CcSEcCtD
Fosaprepitant—Dry mouth—Triamcinolone—psoriatic arthritis	0.00199	0.00199	CcSEcCtD
Fosaprepitant—Angioedema—Betamethasone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Fosaprepitant—Angioedema—Dexamethasone—psoriatic arthritis	0.00198	0.00198	CcSEcCtD
Fosaprepitant—Stomatitis—Methotrexate—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Fosaprepitant—Angiopathy—Prednisone—psoriatic arthritis	0.00197	0.00197	CcSEcCtD
Fosaprepitant—Conjunctivitis—Methotrexate—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Fosaprepitant—Immune system disorder—Prednisone—psoriatic arthritis	0.00196	0.00196	CcSEcCtD
Fosaprepitant—Malaise—Dexamethasone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Malaise—Betamethasone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Oedema—Triamcinolone—psoriatic arthritis	0.00195	0.00195	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Syncope—Betamethasone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Syncope—Dexamethasone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Infection—Triamcinolone—psoriatic arthritis	0.00194	0.00194	CcSEcCtD
Fosaprepitant—Infection—Methylprednisolone—psoriatic arthritis	0.00193	0.00193	CcSEcCtD
Fosaprepitant—Haematuria—Methotrexate—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Fosaprepitant—Shock—Triamcinolone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Fosaprepitant—Insomnia—Prednisolone—psoriatic arthritis	0.00192	0.00192	CcSEcCtD
Fosaprepitant—Shock—Methylprednisolone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00191	0.00191	CcSEcCtD
Fosaprepitant—Loss of consciousness—Betamethasone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Fosaprepitant—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Fosaprepitant—Mental disorder—Prednisone—psoriatic arthritis	0.0019	0.0019	CcSEcCtD
Fosaprepitant—Skin disorder—Methylprednisolone—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Malnutrition—Prednisone—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Erythema—Prednisone—psoriatic arthritis	0.00189	0.00189	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.00188	0.00188	CcSEcCtD
Fosaprepitant—Hypertension—Dexamethasone—psoriatic arthritis	0.00187	0.00187	CcSEcCtD
Fosaprepitant—Hypertension—Betamethasone—psoriatic arthritis	0.00187	0.00187	CcSEcCtD
Fosaprepitant—Anxiety—Betamethasone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Anxiety—Dexamethasone—psoriatic arthritis	0.00184	0.00184	CcSEcCtD
Fosaprepitant—Discomfort—Betamethasone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Discomfort—Dexamethasone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Hypotension—Methylprednisolone—psoriatic arthritis	0.00182	0.00182	CcSEcCtD
Fosaprepitant—Pain—Prednisolone—psoriatic arthritis	0.00181	0.00181	CcSEcCtD
Fosaprepitant—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.00179	0.00179	CcSEcCtD
Fosaprepitant—Urethral disorder—Methotrexate—psoriatic arthritis	0.00178	0.00178	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Oedema—Dexamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Oedema—Betamethasone—psoriatic arthritis	0.00177	0.00177	CcSEcCtD
Fosaprepitant—Insomnia—Triamcinolone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Insomnia—Methylprednisolone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Infection—Dexamethasone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Infection—Betamethasone—psoriatic arthritis	0.00176	0.00176	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Prednisone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisolone—psoriatic arthritis	0.00175	0.00175	CcSEcCtD
Fosaprepitant—Anaemia—Prednisone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Shock—Betamethasone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Shock—Dexamethasone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Dyspnoea—Triamcinolone—psoriatic arthritis	0.00174	0.00174	CcSEcCtD
Fosaprepitant—Nervous system disorder—Betamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.00173	0.00173	CcSEcCtD
Fosaprepitant—Angioedema—Prednisone—psoriatic arthritis	0.00172	0.00172	CcSEcCtD
Fosaprepitant—Dyspepsia—Triamcinolone—psoriatic arthritis	0.00172	0.00172	CcSEcCtD
Fosaprepitant—Erythema multiforme—Methotrexate—psoriatic arthritis	0.00171	0.00171	CcSEcCtD
Fosaprepitant—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00171	0.00171	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00171	0.00171	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00171	0.00171	CcSEcCtD
Fosaprepitant—Malaise—Prednisone—psoriatic arthritis	0.0017	0.0017	CcSEcCtD
Fosaprepitant—Eye disorder—Methotrexate—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Syncope—Prednisone—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Tinnitus—Methotrexate—psoriatic arthritis	0.00169	0.00169	CcSEcCtD
Fosaprepitant—Urticaria—Prednisolone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Cardiac disorder—Methotrexate—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Fatigue—Triamcinolone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Fatigue—Methylprednisolone—psoriatic arthritis	0.00168	0.00168	CcSEcCtD
Fosaprepitant—Pain—Triamcinolone—psoriatic arthritis	0.00167	0.00167	CcSEcCtD
Fosaprepitant—Loss of consciousness—Prednisone—psoriatic arthritis	0.00166	0.00166	CcSEcCtD
Fosaprepitant—Hypotension—Dexamethasone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Fosaprepitant—Hypotension—Betamethasone—psoriatic arthritis	0.00165	0.00165	CcSEcCtD
Fosaprepitant—Angiopathy—Methotrexate—psoriatic arthritis	0.00164	0.00164	CcSEcCtD
Fosaprepitant—Immune system disorder—Methotrexate—psoriatic arthritis	0.00164	0.00164	CcSEcCtD
Fosaprepitant—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Hypertension—Prednisone—psoriatic arthritis	0.00163	0.00163	CcSEcCtD
Fosaprepitant—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.00161	0.00161	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Anxiety—Prednisone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Insomnia—Dexamethasone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Insomnia—Betamethasone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.0016	0.0016	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Fosaprepitant—Discomfort—Prednisone—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Fosaprepitant—Mental disorder—Methotrexate—psoriatic arthritis	0.00159	0.00159	CcSEcCtD
Fosaprepitant—Malnutrition—Methotrexate—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Fosaprepitant—Erythema—Methotrexate—psoriatic arthritis	0.00158	0.00158	CcSEcCtD
Fosaprepitant—Hypersensitivity—Prednisolone—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Dyspepsia—Dexamethasone—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Dyspepsia—Betamethasone—psoriatic arthritis	0.00156	0.00156	CcSEcCtD
Fosaprepitant—Urticaria—Triamcinolone—psoriatic arthritis	0.00155	0.00155	CcSEcCtD
Fosaprepitant—Urticaria—Methylprednisolone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Dysgeusia—Methotrexate—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Body temperature increased—Triamcinolone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Prednisone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Oedema—Prednisone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Decreased appetite—Dexamethasone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Decreased appetite—Betamethasone—psoriatic arthritis	0.00154	0.00154	CcSEcCtD
Fosaprepitant—Infection—Prednisone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.00153	0.00153	CcSEcCtD
Fosaprepitant—Fatigue—Betamethasone—psoriatic arthritis	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Fatigue—Dexamethasone—psoriatic arthritis	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Shock—Prednisone—psoriatic arthritis	0.00152	0.00152	CcSEcCtD
Fosaprepitant—Pain—Betamethasone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Fosaprepitant—Pain—Dexamethasone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Fosaprepitant—Nervous system disorder—Prednisone—psoriatic arthritis	0.00151	0.00151	CcSEcCtD
Fosaprepitant—Skin disorder—Prednisone—psoriatic arthritis	0.0015	0.0015	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Prednisone—psoriatic arthritis	0.00149	0.00149	CcSEcCtD
Fosaprepitant—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Fosaprepitant—Anaemia—Methotrexate—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Fosaprepitant—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Fosaprepitant—Feeling abnormal—Betamethasone—psoriatic arthritis	0.00146	0.00146	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00145	0.00145	CcSEcCtD
Fosaprepitant—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.00144	0.00144	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.00143	0.00143	CcSEcCtD
Fosaprepitant—Malaise—Methotrexate—psoriatic arthritis	0.00142	0.00142	CcSEcCtD
Fosaprepitant—Urticaria—Dexamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Urticaria—Betamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Dizziness—Prednisolone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Asthenia—Triamcinolone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Abdominal pain—Dexamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Abdominal pain—Betamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Body temperature increased—Dexamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Body temperature increased—Betamethasone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Asthenia—Methylprednisolone—psoriatic arthritis	0.0014	0.0014	CcSEcCtD
Fosaprepitant—Insomnia—Prednisone—psoriatic arthritis	0.00139	0.00139	CcSEcCtD
Fosaprepitant—Pruritus—Triamcinolone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Fosaprepitant—Cough—Methotrexate—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Fosaprepitant—Pruritus—Methylprednisolone—psoriatic arthritis	0.00138	0.00138	CcSEcCtD
Fosaprepitant—Dyspepsia—Prednisone—psoriatic arthritis	0.00136	0.00136	CcSEcCtD
Fosaprepitant—Chest pain—Methotrexate—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Decreased appetite—Prednisone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Rash—Prednisolone—psoriatic arthritis	0.00134	0.00134	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisolone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Fatigue—Prednisone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Headache—Prednisolone—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Discomfort—Methotrexate—psoriatic arthritis	0.00133	0.00133	CcSEcCtD
Fosaprepitant—Constipation—Prednisone—psoriatic arthritis	0.00132	0.00132	CcSEcCtD
Fosaprepitant—Dizziness—Triamcinolone—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Dizziness—Methylprednisolone—psoriatic arthritis	0.00129	0.00129	CcSEcCtD
Fosaprepitant—Infection—Methotrexate—psoriatic arthritis	0.00128	0.00128	CcSEcCtD
Fosaprepitant—Feeling abnormal—Prednisone—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Fosaprepitant—Asthenia—Dexamethasone—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Fosaprepitant—Asthenia—Betamethasone—psoriatic arthritis	0.00127	0.00127	CcSEcCtD
Fosaprepitant—Nervous system disorder—Methotrexate—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Nausea—Prednisolone—psoriatic arthritis	0.00126	0.00126	CcSEcCtD
Fosaprepitant—Pruritus—Betamethasone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Pruritus—Dexamethasone—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Skin disorder—Methotrexate—psoriatic arthritis	0.00125	0.00125	CcSEcCtD
Fosaprepitant—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Fosaprepitant—Vomiting—Triamcinolone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Fosaprepitant—Vomiting—Methylprednisolone—psoriatic arthritis	0.00124	0.00124	CcSEcCtD
Fosaprepitant—Rash—Triamcinolone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Dermatitis—Triamcinolone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Rash—Methylprednisolone—psoriatic arthritis	0.00123	0.00123	CcSEcCtD
Fosaprepitant—Dermatitis—Methylprednisolone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Urticaria—Prednisone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Headache—Triamcinolone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Headache—Methylprednisolone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Body temperature increased—Prednisone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Abdominal pain—Prednisone—psoriatic arthritis	0.00122	0.00122	CcSEcCtD
Fosaprepitant—Diarrhoea—Betamethasone—psoriatic arthritis	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Diarrhoea—Dexamethasone—psoriatic arthritis	0.00121	0.00121	CcSEcCtD
Fosaprepitant—Hypotension—Methotrexate—psoriatic arthritis	0.0012	0.0012	CcSEcCtD
Fosaprepitant—Dizziness—Betamethasone—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Fosaprepitant—Dizziness—Dexamethasone—psoriatic arthritis	0.00117	0.00117	CcSEcCtD
Fosaprepitant—Insomnia—Methotrexate—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Nausea—Triamcinolone—psoriatic arthritis	0.00116	0.00116	CcSEcCtD
Fosaprepitant—Nausea—Methylprednisolone—psoriatic arthritis	0.00115	0.00115	CcSEcCtD
Fosaprepitant—Dyspnoea—Methotrexate—psoriatic arthritis	0.00115	0.00115	CcSEcCtD
Fosaprepitant—Somnolence—Methotrexate—psoriatic arthritis	0.00114	0.00114	CcSEcCtD
Fosaprepitant—Hypersensitivity—Prednisone—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Dyspepsia—Methotrexate—psoriatic arthritis	0.00113	0.00113	CcSEcCtD
Fosaprepitant—Vomiting—Betamethasone—psoriatic arthritis	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Vomiting—Dexamethasone—psoriatic arthritis	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Decreased appetite—Methotrexate—psoriatic arthritis	0.00112	0.00112	CcSEcCtD
Fosaprepitant—Rash—Betamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Rash—Dexamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Dermatitis—Dexamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Dermatitis—Betamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Fatigue—Methotrexate—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Headache—Betamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Headache—Dexamethasone—psoriatic arthritis	0.00111	0.00111	CcSEcCtD
Fosaprepitant—Asthenia—Prednisone—psoriatic arthritis	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Pain—Methotrexate—psoriatic arthritis	0.0011	0.0011	CcSEcCtD
Fosaprepitant—Pruritus—Prednisone—psoriatic arthritis	0.00109	0.00109	CcSEcCtD
Fosaprepitant—Feeling abnormal—Methotrexate—psoriatic arthritis	0.00106	0.00106	CcSEcCtD
Fosaprepitant—Diarrhoea—Prednisone—psoriatic arthritis	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Nausea—Betamethasone—psoriatic arthritis	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Nausea—Dexamethasone—psoriatic arthritis	0.00105	0.00105	CcSEcCtD
Fosaprepitant—Urticaria—Methotrexate—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Dizziness—Prednisone—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Abdominal pain—Methotrexate—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Body temperature increased—Methotrexate—psoriatic arthritis	0.00102	0.00102	CcSEcCtD
Fosaprepitant—Vomiting—Prednisone—psoriatic arthritis	0.000979	0.000979	CcSEcCtD
Fosaprepitant—Rash—Prednisone—psoriatic arthritis	0.000971	0.000971	CcSEcCtD
Fosaprepitant—Dermatitis—Prednisone—psoriatic arthritis	0.00097	0.00097	CcSEcCtD
Fosaprepitant—Headache—Prednisone—psoriatic arthritis	0.000965	0.000965	CcSEcCtD
Fosaprepitant—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000948	0.000948	CcSEcCtD
Fosaprepitant—Asthenia—Methotrexate—psoriatic arthritis	0.000923	0.000923	CcSEcCtD
Fosaprepitant—Nausea—Prednisone—psoriatic arthritis	0.000915	0.000915	CcSEcCtD
Fosaprepitant—Pruritus—Methotrexate—psoriatic arthritis	0.000911	0.000911	CcSEcCtD
Fosaprepitant—Diarrhoea—Methotrexate—psoriatic arthritis	0.000881	0.000881	CcSEcCtD
Fosaprepitant—Dizziness—Methotrexate—psoriatic arthritis	0.000851	0.000851	CcSEcCtD
Fosaprepitant—Vomiting—Methotrexate—psoriatic arthritis	0.000818	0.000818	CcSEcCtD
Fosaprepitant—Rash—Methotrexate—psoriatic arthritis	0.000811	0.000811	CcSEcCtD
Fosaprepitant—Dermatitis—Methotrexate—psoriatic arthritis	0.000811	0.000811	CcSEcCtD
Fosaprepitant—Headache—Methotrexate—psoriatic arthritis	0.000806	0.000806	CcSEcCtD
Fosaprepitant—Nausea—Methotrexate—psoriatic arthritis	0.000764	0.000764	CcSEcCtD
